Mirabegron Patent Expiration
Mirabegron is used for treating neurogenic detrusor overactivity in pediatric patients and overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency, including in combination with solifenacin succinate for more severe cases. It was first introduced by Astellas Pharma Global Development Inc
Mirabegron Patents
Given below is the list of patents protecting Mirabegron, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Myrbetriq | US10842780 | Pharmaceutical composition for modified release | Sep 28, 2029 | Apgdi |
| Myrbetriq |
US10842780 (Pediatric) | Pharmaceutical composition for modified release | Mar 28, 2030 | Apgdi |
| Myrbetriq | US11707451 | Pharmaceutical composition for modified release | Sep 28, 2029 | Apgdi |
| Myrbetriq |
US11707451 (Pediatric) | Pharmaceutical composition for modified release | Mar 28, 2030 | Apgdi |
| Myrbetriq | US6346532 | Amide derivatives or salts thereof |
Oct 15, 2018
(Expired) | Apgdi |
| Myrbetriq |
US6346532 (Pediatric) | Amide derivatives or salts thereof |
Sep 27, 2022
(Expired) | Apgdi |
| Myrbetriq | US6562375 | Stable pharmaceutical composition for oral use |
Aug 01, 2020
(Expired) | Apgdi |
| Myrbetriq | US6699503 | Hydrogel-forming sustained-release preparation |
Sep 10, 2013
(Expired) | Apgdi |
| Myrbetriq | US7342117 | α-form or β-form crystal of acetanilide derivative |
Nov 04, 2023
(Expired) | Apgdi |
| Myrbetriq |
US7342117 (Pediatric) | α-form or β-form crystal of acetanilide derivative |
May 04, 2024
(Expired) | Apgdi |
| Myrbetriq | US7750029 | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
Dec 18, 2023
(Expired) | Apgdi |
| Myrbetriq | US7982049 | α-form or β-form crystal of acetanilide derivative |
Nov 04, 2023
(Expired) | Apgdi |
| Myrbetriq |
US7982049 (Pediatric) | α-form or β-form crystal of acetanilide derivative |
May 04, 2024
(Expired) | Apgdi |
| Myrbetriq | US8772315 | Pharmaceutical composition for treating overactive bladder | Oct 30, 2028 | Apgdi |
| Myrbetriq |
US8772315 (Pediatric) | Pharmaceutical composition for treating overactive bladder | Apr 30, 2029 | Apgdi |
| Myrbetriq | US8835474 | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
Nov 04, 2023
(Expired) | Apgdi |
| Myrbetriq |
US8835474 (Pediatric) | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
May 04, 2024
(Expired) | Apgdi |
| Myrbetriq | USRE44872 | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
Nov 04, 2023
(Expired) | Apgdi |
| Myrbetriq |
USRE44872 (Pediatric) | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
May 04, 2024
(Expired) | Apgdi |
| Myrbetriq Granules | US10058536 | Pharmaceutical composition containing mirabegron | Mar 31, 2036 | Apgdi |
| Myrbetriq Granules |
US10058536 (Pediatric) | Pharmaceutical composition containing mirabegron | Oct 01, 2036 | Apgdi |
| Myrbetriq Granules | US6346532 | Amide derivatives or salts thereof |
Mar 27, 2022
(Expired) | Apgdi |
| Myrbetriq Granules |
US6346532 (Pediatric) | Amide derivatives or salts thereof |
Sep 27, 2022
(Expired) | Apgdi |
| Myrbetriq Granules | US7342117 | α-form or β-form crystal of acetanilide derivative |
Nov 04, 2023
(Expired) | Apgdi |
| Myrbetriq Granules |
US7342117 (Pediatric) | α-form or β-form crystal of acetanilide derivative |
May 04, 2024
(Expired) | Apgdi |
| Myrbetriq Granules | US7982049 | α-form or β-form crystal of acetanilide derivative |
Nov 04, 2023
(Expired) | Apgdi |
| Myrbetriq Granules |
US7982049 (Pediatric) | α-form or β-form crystal of acetanilide derivative |
May 04, 2024
(Expired) | Apgdi |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Mirabegron Generics
Several generic applications have been filed for Mirabegron. The first generic version for Mirabegron was by Sawai Usa Inc and was approved on Dec 27, 2019. And the latest generic version is by Alkem Laboratories Ltd and was approved on Feb 12, 2024.
Given below is the list of companies who have filed for Mirabegron generic.
1. LUPIN LTD
Lupin Ltd has filed for 2 different strengths of generic version for Mirabegron. Given below are the details of the strengths of this generic introduced by Lupin Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 25MG | tablet, extended release | Prescription | ORAL | AB | Sep 28, 2022 |
| 50MG | tablet, extended release | Prescription | ORAL | AB | Sep 28, 2022 |
2. SAWAI USA
Sawai Usa Inc has filed for 1 generic for Mirabegron. Given below are the details of the strengths of this generic introduced by Sawai Usa.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 25MG | tablet, extended release | Discontinued | ORAL | N/A | Dec 27, 2019 |
3. ZYDUS PHARMS
Zydus Pharmaceuticals Usa Inc has filed for 2 different strengths of generic version for Mirabegron. Given below are the details of the strengths of this generic introduced by Zydus Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 25MG | tablet, extended release | Prescription | ORAL | AB | Sep 29, 2022 |
| 50MG | tablet, extended release | Prescription | ORAL | AB | Sep 29, 2022 |
4. ALKEM LABS LTD
Alkem Laboratories Ltd has filed for 2 different strengths of generic version for Mirabegron. Given below are the details of the strengths of this generic introduced by Alkem Labs Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 25MG | tablet, extended release | Prescription | ORAL | AB | Feb 12, 2024 |
| 50MG | tablet, extended release | Prescription | ORAL | AB | Feb 12, 2024 |